Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1997-04-04
1999-11-30
Fredman, Jeffrey
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435 912, 436 64, 436813, 536 231, 536 243, 536 2431, 536 2453, C12Q 168, C12P 1934, G01N 3348, C07H 2102
Patent
active
059940719
ABSTRACT:
A method of determining the severity of prostatic cancer includes measuring the level of amplification of the HER-2
eu gene in a sample of prostate tissue by fluorescence in-situ hybridization and comparing the measured level of amplification of the HER-2
eu gene in the sample with the level of HER-2
eu gene in normal prostate tissue. A method for determining treatment for a patient afflicted with prostate cancer includes determining whether the number of copies of HER-2
eu gene in prostate cells from the patient exceeds four by using fluorescence in-situ hybridization and aggressively treating such patient having prostate cells with five or more copies of the HER-2
eu gene.
REFERENCES:
patent: 5616731 (1997-04-01), Lobberding et al.
patent: 5658730 (1997-09-01), McGill et al.
patent: 5705157 (1998-01-01), Greene
Matthews et al, "Analytical Strategies for the useof DNA probes", Anal. Biochem. 169:1-25, 1988.
Descotes et al, "Human Breast Cancer: Correlation study between HER-2
eu amplification and prognostic factors in an unselected population", Anticancer Res. 13:119-124, 1993.
Naraghi et al, "Human prostate cancer overexpression of ErbB2 may be due to HER2
eu gene amplification", Proceedings American Association for Cancer Research 36:A3838, Mar. 1995.
Myers et al, "Serum levels of erbB-2 protein in prostate adenocarcinoma", Proceedings American Association for Cancer research 36:A3838, Mar. 1995.
Paterson et al, "Correlation between c-erbB-2 amplification and risk of ecurrent disease in node-negative breast cancer", Cancer Res. 51:556-567, Jan. 1991.
Ross, J.S., et al.,: Contribution of HER-2
eu Oncogene Expression to Tumor Grade and DNA Content Analysis in the Predication of Prostatic Carcinoma Metastasis. ancer. vol. 72, No. 10, pp. 3020-3028: Nov. 15, 1993.
Kuhn, E.J., et al.,: Expression of the c-erbB-2 (HER-2
eu) Oncoprotein in Human Prostatic Carcinoma. The Journal of Urology. vol. 150, pp. 1427-1433: Nov. 1993.
Ware, J.L., et al.,: Immunohistochemical Detection of c-erbB-2 Protein in Human Benign and Neoplastic Prostate. Human Pathology. vol. 22, No. 3, pp. 254-258: Mar. 1991.
Battifor, H., et al.,: Immunohistochemical Assay of neu/c-erbB-2 Oncogene Product in Paraffin-embedded Tissues in Early Brest CancerRetrospective Follow-up Study of 245 Stage I and II cases. Modern Pathology. vol. 4, No. 4, pp. 466-474: 1991.
Sadasivan, R., et al.,: Overexpression of HER-2
eu may be an indicator of Poor Prognosis in Prostate Cancer. The Journal of Urology. vol. 150, pp. 126-131: Jul. 1994.
Takahashi, S., et al.,: Potential Markers of Prostate Cancer Aggressiveness Detected by Fluorescence In Situ Hybridization in Needle Biopsies. Cancer Research. vol. 54, pp. 3574-3579: Jul. 1, 1994.
Xiao, S., et al.,: Novel Fluorescence in Situ Hybridization Approaches in Solid Tumors--Characterization of Frozen Specimens, Touch Preparation, and Cytological Preparations. American Journal of Pathology, vol. 147, No. 4, pp. 896-904: Oct. 1995.
ian, J., et al.,: Chromosomal Anomalies in Prostatic Intraepithelial Neoplasia and Carcinoma Detected by Fluorescence in Situ Hybridization. Cancer research. vol. 55, pp. 5408-5414: Nov. 15, 1995.
Brown, J.A., et al.,: Chromosomal Aneusomies Detected by Fluorescent In Situ Hybridization Analysis in Clinically Localized Prostate Carcinoma. The Journal of Urology. vol. 152, pp. 1157-1192: Oct. 1994.
Visakorpi, T., et al.,: Expression of Epidermal Growth Factor Receptor and ERBB2 (HER-2/Neu) Oncoprotein in Prostatic Carcinomas. Modern Pathoogy. vol. 5, No. 6, pp. 643-648: 1992.
Zitzelsberger, H., et al.,: Numerical Abnormalities of Chromosome 7 in Human Prostate Cancer Detected by Fluorescence In Situ Hybridization (FISH) on Paraffin-Embedded Tissue Sections with Centromere-specific DNA Probes. Journal of Pathology. vol. 172, pp. 325-335: 1994.
Latil, Fournier G., et al.,: Gene Amplification in Advanced-Stage Human Prostate Cancer. Urol Res. vol. 22, No. 6, pp. 343-347: 1995.
Lyne, J.C., et al.,: Tissue Expression of neu Differentaition Factor/Heregulin and its Receptor Complex in Prostate Cancer and its Biological Effects on Prostate Cancer Cells In Vitro. Cancer Journal From Scientific American. vol. 3 No. 1, pp. 21-30: 1997.
Muller, P., et al.,: Detection of Genetic Alterations in Micrometastic Cells in Bone Marrow of Cancer Patients by Fluorescence In Situ Hybridization. Cancer Genetics & Cytogenetics. vol. 88 No. 1, pp. 8-16: 1996.
Veltri, R.W., et al.,: Abnormal Expression of a Truncated Intracellular HER-2
eu mRNA in Prostate Cancer. Proc. Annu Meet Am Assoc. Cancer Res., vol. 37, p. A572: 1996.
Zhau, H.E., et al.,: Biomarkers Associated with Prostate Cancer Progression. Journal of Cellular Biochemistry. Supplement, vol. 19, pp. 208-216: 1994.
Muraca Patrick J.
Ross Jeffrey S.
Albany Medical College
Cohan Jonathan M.
Fredman Jeffrey
Tarcza John E.
Ventana Medical Systems, Inc.
LandOfFree
Assessment of prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assessment of prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assessment of prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1670079